Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The breastfeeding-related claims include some label-consistent guidance (avoid breastfeeding during treatment and for 2 weeks after the last dose), but several statements are either not supported by the provided label excerpts or are overly general/indefinite (e.g., “not well established,” “limited direct data,” “critical interval”) without matching the specific labeled 2-week timeframe.
Category Scores
Accurate Statements
Clinicians avoid breastfeeding during lurbinectedin treatment and for a period after the last dose unless an oncology team confirms it is safe for a specific patient.
Supported partially: Label advises women not to breastfeed during treatment and for 2 weeks after the last dose (Section 8.2). Label does not state that oncology team “confirmation” can make breastfeeding safe.
Lurbinectedin transfer into breast milk and potential effects on a breastfed infant are a key concern.
Supported in concept: Label states potential for serious adverse reactions in breastfed children (Section 8.2).
The interval for how long after the final dose to resume breastfeeding is critical.
Supported in concept: Label specifies not to breastfeed for 2 weeks after the last dose (Section 8.2).
Unsupported Statements
Lurbinectedin safety during breastfeeding is not well established.
The provided label excerpt (Section 8.2) gives a direct recommendation not to breastfeed during treatment and for 2 weeks after the last dose; it does not state safety is “not well established.”
There is limited direct breastfeeding data for lurbinectedin.
No such statement appears in the provided label excerpts (Section 8.2 or other included sections).
Clinicians avoid breastfeeding during lurbinectedin treatment and for a period after the last dose unless an oncology team confirms it is safe for a specific patient.
Section 8.2 provides an explicit recommendation not to breastfeed during treatment and for 2 weeks after the last dose; it does not describe case-by-case exceptions based on oncology team confirmation.
For many chemotherapy agents, the possibility that the drug (or active metabolites) could reach the infant through breast milk is a reason breastfeeding is avoided.
This is generalized/attributed rationale not stated in the provided label excerpts for ZEPZELCA.
The described concern with chemotherapy agents is that they could affect rapidly dividing cells in the infant and potentially cause harm.
Not stated in the provided label excerpts.
There is not enough publicly available breastfeeding information for lurbinectedin to provide a definitive 'safe' recommendation based on dose-to-infant exposure.
The provided label excerpt (Section 8.2) is a definitive recommendation to avoid breastfeeding during treatment and for 2 weeks after the last dose; it does not frame the issue as lack of information or dose-to-infant exposure limitations.
Oncology teams commonly discuss pausing or stopping breastfeeding during lurbinectedin treatment.
The label provides patient advice (Section 8.2) but does not support a statement about how oncology teams “commonly discuss” this.
Oncology teams commonly discuss using expressed milk or formula during lurbinectedin treatment depending on timing and guidance from treating clinicians.
The provided label excerpt (Section 8.2) does not mention expressed milk/formula or any timing-dependent alternative feeding guidance.
Contradictions
Low
AI Statement
Clinicians avoid breastfeeding during lurbinectedin treatment and for a period after the last dose unless an oncology team confirms it is safe for a specific patient.
Label Reference
Section 8.2 (Lactation): advise women not to breastfeed during treatment with ZEPZELCA and for 2 weeks after the last dose.
Important Omissions
Explicit labeled interval: “not to breastfeed during treatment with ZEPZELCA and for 2 weeks after the last dose.”
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response generally promotes avoiding breastfeeding, but includes an unsupported notion of case-by-case exceptions (“unless… confirms it is safe”) and does not clearly state the specific labeled 2-week post-dose interval.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Breastfeeding duration is not explicitly aligned to the labeled “2 weeks after the last dose,” and the claim about oncology-team confirmation for exceptions is not supported by the label.
Suggested Improvement
State that women should not breastfeed during treatment with ZEPZELCA and for 2 weeks after the last dose (Section 8.2), without implying individualized exceptions based on oncology team confirmation, and avoid adding unsupported generalizations about chemotherapy or expressed milk/formula.